Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study

Thrombosis and Haemostasis

Volumn 84, Issue 4, 2000, Pages 553-558

  Lowe, G D O ^a   Rumley, A ^a   Norrie, J ^a   Ford, I ^a   Shepherd, J ^a   Cobbe, S ^a   Macfarlane, P ^a   Packard, C ^a   Lorimer, A R ^a   McKillop, J H ^a   Isles, C G ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Coronary heart disease; Lipoproteins; Pravastatin; Rheology; Viscosity

Indexed keywords

FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD RHEOLOGY; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INHIBITION; HEMATOCRIT; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMA VISCOSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING HABIT; TREATMENT OUTCOME;

EID: 0033786331     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614066     Document Type: Article

References (31)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
2. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study
3. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms
4. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
5. Blood rheology and vascular disease
6. Statins do more than just lower cholesterol
7. Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinaemia
8. Cardiovascular risk and haemorheology: Results from the Scottish Heart Health Study and the MONICA-Project, Glasgow
9. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina
10. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies
11. Association between rheology and components of lipoproteins in human blood
12. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. The Caerphilly and Speedwell Studies
13. Blood viscosity and risk of cardiovascular events: The Edinburgh Artery Study
14. Plasma viscosity and the risk of coronary heart disease: Results from the MONICA-Augsburg cohort study, 1984 to 1992
15. A coronary primary prevention study of Scottish men age 45-64 years: Trial design
16. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study
17. A new red-sensitive micronephelometer
18. Plasma fibrinogen: A major coronary risk factor
19. Whole-blood viscosity, as determined by plasma viscosity, hematocrit, and shear
20. Blood viscosity, fibrinogen and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study
21. Fibrinogen, C-reactive protein, albumin or white cell count: Meta-analyses of prospective studies of coronary heart disease
22. Haematocrit, viscosity, erythrocyte sedimentation rate: Meta-analyses of prospective studies of coronary heart disease
23. Fibrinogen as a risk factor for coronary heart disease and mortality in middle aged men and women - The Scottish Heart Health Study
24. Abnormalities of blood rheology in familial hypercholesterolaemia: Effects of treatment
25. Influence of pravastatin and plasma lipids on clinical events in WOSCOPS
26. Effect of three fibrate derivatives and two HMG - CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolaemia
27. Anti-atherothrombotic properties of statins. Implications for cardiovascular event reduction
28. Chronisch-intermittierende urokinasetherapie bei therapierefraktaner angina pectoris
29. Blood viscosity and elevated carotid intima-media thickness in men and women: The Edinburgh Artery Study
30. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C-reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)